InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
T+90 hit rate
50%
T+90 mean return
-10.0%
Across 24 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Hansen Gwenn, Chief Scientific Officer. Officer active across 1 company, notably Nurix Therapeutics, Inc.. In total, 38 disclosures have been logged. Split: 0 buy · 1 sell. Activity tracked since 3 May 2021. The latest transaction was filed on 30 October 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations38 total
5,394 sharesCommon StockSEC:0001817160-26-000010:0
3,207 shares0Common StockSEC:0001817160-25-000005
3,207 shares0Common StockSEC:0001817160-25-000005:0
3,206 shares0Common StockSEC:0001549595-25-000061:0
3,207 shares0Common StockSEC:0001549595-25-000022:0
3,207 shares0Common StockSEC:0001549595-24-000147:0
3,207 shares0Common StockSEC:0001549595-24-000106:0
3,206 shares0Common StockSEC:0001549595-24-000054:0
3,207 shares0Common StockSEC:0001549595-24-000008:0
3,207 shares0Common StockSEC:0001549595-23-000058:0
3,207 shares0Common StockSEC:0001209191-23-043975:0
3,206 shares0Common StockSEC:0001209191-23-026515:0
3,207 shares0Common StockSEC:0001209191-23-005904:0
3,207 shares0Common StockSEC:0001209191-22-055138:0
3,207 shares0Common StockSEC:0001209191-22-043961:0
3,206 shares0Common StockSEC:0001209191-22-026892:0
400 shares@ US$7.263.5% of flowCommon StockSEC:0001209191-22-000730
400 shares@ US$7.260.0001% mcap3.5% of flowCommon StockSEC:0001209191-22-000730:0
400 shares@ US$7.260.0001% mcap3.5% of flowCommon StockSEC:0001209191-21-067685:0
400 shares@ US$7.263.5% of flowCommon StockSEC:0001209191-21-067685
400 shares@ US$7.260.0001% mcap3.4% of flowCommon StockSEC:0001209191-21-062466:0
400 shares@ US$7.263.4% of flowCommon StockSEC:0001209191-21-062466
400 shares@ US$7.260.0001% mcap3.4% of flowCommon StockSEC:0001209191-21-061973:0
400 shares@ US$7.263.4% of flowCommon StockSEC:0001209191-21-061973
400 shares@ US$7.260.0001% mcap3.4% of flowCommon StockSEC:0001209191-21-059064:0
25 of 38 declarations
About Hansen Gwenn
Hansen Gwenn is the Chief Scientific Officer of Nurix Therapeutics, Inc. He oversees the company's research and development initiatives.
